argenx (NASDAQ:ARGX) Price Target Raised to $1,100.00

argenx (NASDAQ:ARGX) had its price target hoisted by Guggenheim from $775.00 to $1,100.00 in a research report sent to investors on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms have also issued reports on ARGX. Wedbush restated an “outperform” rating and issued a $655.00 target price on shares of argenx in a report on Tuesday, December 3rd. JMP Securities increased their price objective on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 14th. William Blair reiterated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Oppenheimer increased their price objective on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Finally, HC Wainwright increased their price objective on shares of argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Trading Up 1.9 %

NASDAQ:ARGX opened at $591.45 on Monday. The firm has a market cap of $35.94 billion, a price-to-earnings ratio of -672.10 and a beta of 0.59. The company’s 50-day moving average is $639.78 and its two-hundred day moving average is $595.30. argenx has a 12-month low of $349.86 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities research analysts forecast that argenx will post 3.13 earnings per share for the current fiscal year.

Institutional Trading of argenx

Large investors have recently bought and sold shares of the company. GeoWealth Management LLC grew its position in argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after acquiring an additional 18 shares in the last quarter. Whipplewood Advisors LLC acquired a new stake in argenx in the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC grew its position in argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after acquiring an additional 48 shares in the last quarter. FIL Ltd purchased a new position in shares of argenx during the 4th quarter valued at approximately $38,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of argenx during the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.